The current exercise led to the identification of research questions that are mostly related to implementation of existing interventions and the development of simplified, more cost-effective versions of existing interventions (e.g. oxytocin and misoprostol for PPH prevention and treatment or magnesium sulfate for eclampsia). The gene discussed is OXT; the disease is pulmonary arterial hypertension.